Blueprint Medicines Corporation
BPMC
$88.61
-$1.40-1.56%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 14.18% | -7.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.18% | -7.22% | |||
| Cost of Revenue | 285.46% | -74.56% | |||
| Gross Profit | 10.03% | -3.30% | |||
| SG&A Expenses | 7.25% | 0.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.88% | -2.23% | |||
| Operating Income | 15.87% | -13.77% | |||
| Income Before Tax | 12.00% | -12.25% | |||
| Income Tax Expenses | 146.15% | 167.65% | |||
| Earnings from Continuing Operations | 11.23% | -12.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.23% | -12.57% | |||
| EBIT | 15.87% | -13.77% | |||
| EBITDA | 17.53% | -14.41% | |||
| EPS Basic | 11.53% | -11.63% | |||
| Normalized Basic EPS | -29.28% | -11.26% | |||
| EPS Diluted | 11.53% | -10.99% | |||
| Normalized Diluted EPS | -29.28% | -11.26% | |||
| Average Basic Shares Outstanding | 0.35% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.35% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
